JPMorgan Europe Research Enhanced Index Equity UCITS ETF - EUR (acc) EUR is a equity ETF from JPMorgan tracking the Europe Research Enhanced Index Equity index through physical replication. Domiciled in Ireland and launched in 2018, the fund manages about 2.8 bn € and charges a TER of 0.25% — 25 € per year on a €10,000 investment. Income is automatically reinvested in the fund (accumulating).
JPMorgan Europe Research Enhanced Index Equity UCITS ETF - EUR (acc) EUR competes with 1 other products on the same index (Europe Research Enhanced Index Equity): it ranks 1st by fund size and 1st by ongoing cost, with a TER of 0.25% against a group median of 0.25%. It has been listed since 2018, 8 years of track record.
On a €10,000 investment the TER costs 25 € a year, and no product in the group costs less.
Replication is physical: the fund holds the underlying securities directly. The ten largest positions account for 24.0% of the portfolio.
Income is accumulated: no distribution is paid out, the share price absorbs it. In a savings plan this removes the need to reinvest dividends by hand. The fund is denominated in EUR. That is not the same as currency risk: the exposure comes from the currencies of the underlying holdings, not from the denomination or the trading currency of a given listing.
The fund is domiciled in Ireland, which determines the tax treatment of income received by the fund and the supervisory authority.
| ASML Holding N.V. | 5.1% |
| AstraZeneca PLC | 2.4% |
| Siemens Aktiengesellschaft | 2.3% |
| Shell plc | 2.2% |
| HSBC Holdings PLC | 2.2% |
| Nestle S.A. | 2.1% |
| Allianz SE VNA O.N. | 2.0% |
| Roche Holding AG | 2.0% |
| Novartis AG | 1.9% |
| Infineon Technologies AG | 1.8% |
| Borsa Italiana | JREE | EUR |
| XETRA | JREE | EUR |
| Francoforte | JREE | EUR |
| London Stock Exchange | JERE | GBX |
| London Stock Exchange | JREE | EUR |
| SIX Swiss Exchange | JREE | EUR |
Source: the fund's KID and the issuer's official documentation — data verified as of July 2026.
This page is informational and is not an investment recommendation. Figures may contain errors or be out of date: always check the KID and the issuer's factsheet before any decision.